Neumora Therapeutics (NMRA) Corporate presentation summary

Mission and leadership

• Focus on developing next-generation, brain-penetrant therapies to improve outcomes and quality of life for patients with neurological and psychiatric disorders.

• Led by experienced executives and board members with backgrounds in major pharmaceutical and biotech companies.

Strategic focus and market opportunity

• Targeting large unmet needs in neuropsychiatric, neurodegenerative, and cardiometabolic diseases, which impact millions in the U.S.

• Programs address obesity, cardiovascular risk, Alzheimer's agitation, Parkinson's, and schizophrenia.

Pipeline and clinical progress

• Advancing three main franchises: NMRA-215 (NLRP3 inhibitor for obesity/CV risk), NMRA-511 (V1aR antagonist for Alzheimer's agitation), and NMRA-898 (M4 modulator for schizophrenia).

• NMRA-215 shows class-leading weight loss, improved metabolic biomarkers, and sustained effects in preclinical models, with IND submission and Phase 1 initiation planned for late 2026.

• NMRA-511 demonstrates unsurpassed efficacy and favorable safety in Alzheimer's agitation, with potential for higher dosing and future studies targeting elevated anxiety populations.

• NMRA-898 exhibits best-in-class potency, optimized brain penetration, and promising Phase 1 results, with further data expected in 2H 2026.